BCLXL-PROTAC as a senolytic therapy in COPD alveolar type II cells

Koralia Paschalaki, Konstantinos Evangelou, Dimitris Veroutis, Periklis Foukas, Christos Kittas, Athanasios G. Tzioufas, Laurence de Leval, Demetris Vassilakos, Peter J Barnes, Vassilis G. Gorgoulis

BCLXL-PROTAC as a senolytic therapy in COPD alveolar type II cells

Discussion(0)

Related publications

Effect of the novel senolytic drug, BCL-xL PROTAC, on small airway epithelial cells in COPD

Effect of the novel senolytic drug, BCL-xL-PROTAC, on small airway fibroblasts in COPD

Navitoclax inhibits senescence in human alveolar type 2 cells from COPD patients

Alveolar Macrophages as Orchestrators of COPD

Alveolar type II cells harbouring SARS-CoV-2 show senescence with a proinflammatory phenotype